Differential dopamine receptor occupancy underlies L-DOPA-induced dyskinesia in a rat model of parkinson's disease

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Sahin, Gurdal ^a   Thompson, Lachlan H ^a,b   Lavisse, Sonia ^c   Ozgur, Merve ^a   Rbah Vidal, Latifa ^c   Dollé, Frédéric ^d   Hantraye, Philippe ^c   Kirik, Deniz ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^d SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 2 RECEPTOR; LEVODOPA; BENZAMIDE DERIVATIVE; DOPAMINE; DOPAMINE RECEPTOR; FOSB PROTEIN, RAT; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; NOMIFENSINE; PROTEIN C FOS; PYRROLIDINE DERIVATIVE; SEROTONIN;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL TRANSPLANTATION; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DYSKINESIA; FEMALE; IN VIVO STUDY; MICRODIALYSIS; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; RAT; SEROTONINERGIC NERVE CELL; YOUNG ADULT; ANIMAL; DISEASE MODEL; DRUG EFFECTS; EXTRACELLULAR SPACE; METABOLISM; NEOSTRIATUM; PATHOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; EXTRACELLULAR SPACE; FEMALE; LEVODOPA; MICRODIALYSIS; NEOSTRIATUM; NOMIFENSINE; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PROTO-ONCOGENE PROTEINS C-FOS; PYRROLIDINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SEROTONIN;

EID: 84897488054     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090759     Document Type: Article

References (65)

1. Fahn S (2003) Description of Parkinson's disease as a clinical syndrome. Annals of the New York Academy of Sciences 991: 1-14.
2. Kim DS, Palmiter RD, Cummins A, Gerfen CR (2006) Reversal of supersensitive striatal dopamine D1 receptor signaling and extracellular signal-regulated kinase activity in dopamine-deficient mice. Neuroscience 137: 1381-1388. (Pubitemid 43133161)
3. Winkler C, Kirik D, Bjorklund A, Cenci MA (2002) L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiology of disease 10: 165-186. (Pubitemid 34775470)
4. Rice ME, Patel JC, Cragg SJ (2011) Dopamine release in the basal ganglia. Neuroscience 198: 112-137.
5. Gerfen CR, Miyachi S, Paletzki R, Brown P (2002) D1 dopamine receptor supersensitivity in the dopamine-depleted striatum results from a switch in the regulation of ERK1/2/MAP kinase. The Journal of neuroscience: the official journal of the Society for Neuroscience 22: 5042-5054.
6. Aubert I, Guigoni C, Hakansson K, Li Q, Dovero S, et al. (2005) Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of neurology 57: 17-26. (Pubitemid 40053311)
7. Westin JE, Vercammen L, Strome EM, Konradi C, Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biological psychiatry 62: 800-810. (Pubitemid 47374647)
8. Navailles S, Bioulac B, Gross C, De Deurwaerdere P (2010) Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease. Neurobiology of disease 38: 136-143.
9. Garcia J, Carlsson T, Dobrossy M, Nikkhah G, Winkler C (2011) Impact of dopamine to serotonin cell ratio in transplants on behavioral recovery and L-DOPA-induced dyskinesia. Neurobiology of disease 43: 576-587.
10. Carlsson T, Carta M, Winkler C, Bjorklund A, Kirik D (2007) Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. The Journal of neuroscience: the official journal of the Society for Neuroscience 27: 8011-8022.
11. Lindgren HS, Andersson DR, Lagerkvist S, Nissbrandt H, Cenci MA (2010) L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson's disease: temporal and quantitative relationship to the expression of dyskinesia. Journal of neurochemistry 112: 1465-1476.
12. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, et al. (2009) The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 63: 610-620.
13. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, et al. (1999) Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 10: 631-634. (Pubitemid 29333295)
14. Ng KY, Chase TN, Colburn RW, Kopin IJ (1970) L-Dopa-induced release of cerebral monoamines. Science 170: 76-77.
15. Everett GM, Borcherding JW (1970) L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science 168: 847-850.
16. Arai R, Karasawa N, Geffard M, Nagatsu T, Nagatsu I (1994) Immunohisto-chemical evidence that central serotonin neurons produce dopamine from exogenous L-DOPA in the rat, with reference to the involvement of aromatic Lamino acid decarboxylase. Brain research 667: 295-299.
17. Munoz A, Li Q, Gardoni F, Marcello E, Qin C, et al. (2008) Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain: a journal of neurology 131: 3380-3394.
18. Constantinescu CC, Coleman RA, Pan ML, Mukherjee J (2011) Striatal and extrastriatal microPET imaging of D2/D3 dopamine receptors in rat brain with [(1)(8)F]fallypride and [(1)(8)F]desmethoxyfallypride. Synapse 65: 778-787.
19. Christian BT, Narayanan TK, Shi B, Mukherjee J (2000) Quantitation of striatal and extrastriatal D-2 dopamine receptors using PET imaging of [(18)F]fallypride in nonhuman primates. Synapse 38: 71-79. (Pubitemid 30659620)
20. Mukherjee J, Christian BT, Narayanan TK, Shi B, Collins D (2005) Measurement of d-amphetamine-induced effects on the binding of dopamine D-2/D-3 receptor radioligand, 18F-fallypride in extrastriatal brain regions in non-human primates using PET. Brain Res 1032: 77-84. (Pubitemid 40170311)
21. Slifstein M, Kegeles LS, Xu X, Thompson JL, Urban N, et al. (2010) Striatal and extrastriatal dopamine release measured with PET and [(18)F] fallypride. Synapse 64: 350-362.
22. Mukherjee J, Yang ZY, Das MK, Brown T (1995) Fluorinated benzamide neuroleptics-III. Development of (S)-N-[(1-allyl-2-pyrrolidinyl)methyl]-5-(3- [18F]fluoropropyl)-2, 3-dimethoxybenzamide as an improved dopamine D-2 receptor tracer. Nuclear medicine and biology 22: 283-296.
23. Kuhnast B, Hinnen F, Dollé F (2009) Production of [18F]Fallypride on a TRACERLab FX-FN synthesizer J Label Compounds Radiopharm 52 (Suppl. 1): S286.
24. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, et al. (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 16: 834-840.
25. Thorre K, Pravda M, Sarre S, Ebinger G, Michotte Y (1997) New antioxidant mixture for long term stability of serotonin, dopamine and their metabolites in automated microbore liquid chromatography with dual electrochemical detection. Journal of chromatography B, Biomedical sciences and applications 694: 297-303. (Pubitemid 27289502)
26. Ulusoy A, Sahin G, Kirik D (2010) Presynaptic dopaminergic compartment determines the susceptibility to L-DOPA-induced dyskinesia in rats. Proceedings of the National Academy of Sciences of the United States of America 107: 13159-13164.
27. West MJ (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22: 51-61.
28. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147: 229-263.
29. Paxinos G, Watson C (1997) The Rat Brain in Stereotaxic Coordinates. Sydney: Academic Press.
30. Pinheiro J, Bates D (2000) Mixed-effects models in S and S-PLUS. New York, NY [u.a.]: Springer.
31. R-Core-Team (2012) R: A Language and Environment for Statistical Computing.
32. Hothorn T, Bretz F, Westfall P (2008) Simultaneous inference in general parametric models. Biom J 50: 346-363.
33. Cederfjall E, Sahin G, Kirik D (2011) Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of disease.
34. Carta M, Bezard E (2011) Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia. Neuroscience 198: 245-251.
35. Navailles S, De Deurwaerdere P (2011) Presynaptic control of serotonin on striatal dopamine function. Psychopharmacology 213: 213-242.
36. Stocchi F, Vacca L, Ruggieri S, Olanow CW (2005) Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol 62: 905-910. (Pubitemid 40973452)
37. Darmopil S, Martin AB, De Diego IR, Ares S, Moratalla R (2009) Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biological psychiatry 66: 603-613.
38. Muriel MP, Bernard V, Levey AI, Laribi O, Abrous DN, et al. (1999) Levodopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease. Annals of neurology 46: 103-111. (Pubitemid 29314388)
39. St-Hilaire M, Landry E, Levesque D, Rouillard C (2005) Denervation and repeated L-DOPA induce complex regulatory changes in neurochemical phenotypes of striatal neurons: implication of a dopamine D1-dependent mechanism. Neurobiology of disease 20: 450-460. (Pubitemid 41476271)
40. Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, et al. (1993) Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proceedings of the National Academy of Sciences of the United States of America 90: 8861-8865. (Pubitemid 23306410)
41. Yung KK, Bolam JP, Smith AD, Hersch SM, Ciliax BJ, et al. (1995) Immunocytochemical localization of D1 and D2 dopamine receptors in the basal ganglia of the rat: light and electron microscopy. Neuroscience 65: 709-730.
42. Mela F, Marti M, Bido S, Cenci MA, Morari M (2012) In vivo evidence for a differential contribution of striatal and nigral D1 and D2 receptors to L-DOPA induced dyskinesia and the accompanying surge of nigral amino acid levels. Neurobiology of disease 45: 573-582.
43. Hersch SM, Ciliax BJ, Gutekunst CA, Rees HD, Heilman CJ, et al. (1995) Electron microscopic analysis of D1 and D2 dopamine receptor proteins in the dorsal striatum and their synaptic relationships with motor corticostriatal afferents. The Journal of neuroscience: the official journal of the Society for Neuroscience 15: 5222-5237.
44. Caille I, Dumartin B, Bloch B (1996) Ultrastructural localization of D1 dopamine receptor immunoreactivity in rat striatonigral neurons and its relation with dopaminergic innervation. Brain research 730: 17-31. (Pubitemid 26305320)
45. Nahimi A, Holtzermann M, Landau AM, Simonsen M, Jakobsen S, et al. (2012) Serotonergic modulation of receptor occupancy in rats treated with l-DOPA after unilateral 6-OHDA lesioning. Journal of neurochemistry 120: 806-817.
46. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism 20: 423-451.
47. Chergui K, Suaud-Chagny MF, Gonon F (1994) Nonlinear relationship between impulse flow, dopamine release and dopamine elimination in the rat brain in vivo. Neuroscience 62: 641-645.
48. Suaud-Chagny MF, Dugast C, Chergui K, Msghina M, Gonon F (1995) Uptake of dopamine released by impulse flow in the rat mesolimbic and striatal systems in vivo. Journal of neurochemistry 65: 2603-2611.
49. Gonon F (1997) Prolonged and extrasynaptic excitatory action of dopamine mediated by D1 receptors in the rat striatum in vivo. The Journal of neuroscience: the official journal of the Society for Neuroscience 17: 5972-5978.
50. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996) Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379: 606-612. (Pubitemid 26052818)
51. Jones SR, Gainetdinov RR, Wightman RM, Caron MG (1998) Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. The Journal of neuroscience: the official journal of the Society for Neuroscience 18: 1979-1986.
52. Dumartin B, Caille I, Gonon F, Bloch B (1998) Internalization of D1 dopamine receptor in striatal neurons in vivo as evidence of activation by dopamine agonists. The Journal of neuroscience: the official journal of the Society for Neuroscience 18: 1650-1661.
53. Dumartin B, Jaber M, Gonon F, Caron MG, Giros B, et al. (2000) Dopamine tone regulates D1 receptor trafficking and delivery in striatal neurons in dopamine transporter-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 97: 1879-1884. (Pubitemid 30118537)
54. Freund TF, Powell JF, Smith AD (1984) Tyrosine hydroxylase-immunoreactive boutons in synaptic contact with identified striatonigral neurons, with particular reference to dendritic spines. Neuroscience 13: 1189-1215. (Pubitemid 15198966)
55. Moss J, Bolam JP (2008) A dopaminergic axon lattice in the striatum and its relationship with cortical and thalamic terminals. The Journal of neuroscience: the official journal of the Society for Neuroscience 28: 11221-11230.
56. Sesack SR, Aoki C, Pickel VM (1994) Ultrastructural localization of D2 receptor-like immunoreactivity in midbrain dopamine neurons and their striatal targets. The Journal of neuroscience: the official journal of the Society for Neuroscience 14: 88-106.
57. Descarries L, Soghomonian JJ, Garcia S, Doucet G, Bruno JP (1992) Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine. Brain Res 569: 1-13.
58. Lee CS, Cenci MA, Schulzer M, Bjorklund A (2000) Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain: a journal of neurology 123 (Pt 7): 1365-1379.
59. Carlsson T, Winkler C, Lundblad M, Cenci MA, Bjorklund A, et al. (2006) Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiology of disease 21: 657-668. (Pubitemid 43277547)
60. Lane EL, Winkler C, Brundin P, Cenci MA (2006) The impact of graft size on the development of dyskinesia following intrastriatal grafting of embryonic dopamine neurons in the rat. Neurobiology of disease 22: 334-345.
61. Carlsson T, Carta M, Munoz A, Mattsson B, Winkler C, et al. (2009) Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration. Brain: a journal of neurology 132: 319-335.
62. Andersson M, Hilbertson A, Cenci MA (1999) Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiology of disease 6: 461-474. (Pubitemid 30036616)
63. Pavon N, Martin AB, Mendialdua A, Moratalla R (2006) ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biological psychiatry 59: 64-74. (Pubitemid 43005237)
64. Cao X, Yasuda T, Uthayathas S, Watts RL, Mouradian MM, et al. (2010) Striatal overexpression of DeltaFosB reproduces chronic levodopa-induced involuntary movements. The Journal of neuroscience: the official journal of the Society for Neuroscience 30: 7335-7343.
65. Moratalla R, Elibol B, Vallejo M, Graybiel AM (1996) Network-level changes in expression of inducible Fos-Jun proteins in the striatum during chronic cocaine treatment and withdrawal. Neuron 17: 147-156. (Pubitemid 26251599)